Roche Buys Rights to Potential Ocular Therapy

24.08.2016 - Swiss drugmaker Roche has agreed to pay a total of around $270 million to gain access to Eleven Biotherapeutics’ potential eye treatment EBI-031. A humanized monoclonal antibody...